Embattled Biotechs Facing Uncertainty at the FDA Look to Collaborative Deal Structures

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of retirements and layoffs at the FDA could present their greatest challenge yet….
By: Troutman Pepper Locke